Gilde Healthcare buys majority stake in Klifo

Gilde stated that the deal should help build on the company's success to date and facilitate the next steps in its expansion. Klifo will notably look to deepen its service offering and geographical footprint, the GP said, through organic investments and an active buy-and-build strategy. Klifo's management team will continue unchanged, with CEO Alejandra Mørk remaining a significant shareholder.

Gilde Healthcare manages in excess of €1.4bn across two fund strategies: private equity and venture & growth. On the PE side, the GP invests via Gilde Healthcare Services III, which held a final close in March 2019 on €200m and targets lower-mid-market healthcare providers and medical product suppliers with EBITDA of €2-15m and revenues of €10-30m. The fund deploys equity tickets of €10-40m.

Gilde Healthcare recently acquired Germany-based Acti-Med, a developer and contract manufacturer of medical and pharmaceutical devices. It marked the fourth investment from Gilde Healthcare Services III, following Eetgemak, Ace Pharmaceuticals and Tandarts Today.

Company
Klifo is a drug development consultancy mainly based in Denmark, with growing operations in the rest of northern Europe. Headquartered in Copenhagen, the company also has offices in Sweden, Germany and the Netherlands.

Klifo offers multidisciplinary consulting and operational services allowing pharmaceutical companies, biotechs and medical device companies to bring their products to market. Its services cover a number of areas including clinical research, clinical operations, clinical trial supply, quality assurance and regulatory affairs.

The business was founded in 1994 and employs more than 150 staff.

People
Gilde Healthcare – Rafael Natanek (partner).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Buyouts
• Healthcare
• Nordics
• Gilde Buy Out Partners
• Denmark